SGMO vs. EBS, RIGL, CDXS, XOMA, IRWD, VNDA, VSTM, LXRX, ACHV, and RGLS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs.
Sangamo Therapeutics (NASDAQ:SGMO) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk.
Sangamo Therapeutics currently has a consensus target price of $5.17, indicating a potential upside of 351.24%. Emergent BioSolutions has a consensus target price of $14.33, indicating a potential upside of 78.99%. Given Sangamo Therapeutics' higher possible upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than Emergent BioSolutions.
Sangamo Therapeutics has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions has a net margin of -18.55% compared to Sangamo Therapeutics' net margin of -257.87%. Emergent BioSolutions' return on equity of -9.91% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.
In the previous week, Emergent BioSolutions had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Emergent BioSolutions and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 1.02 beat Emergent BioSolutions' score of 0.59 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Sangamo Therapeutics received 29 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.77% of users gave Emergent BioSolutions an outperform vote while only 62.76% of users gave Sangamo Therapeutics an outperform vote.
Summary
Sangamo Therapeutics and Emergent BioSolutions tied by winning 9 of the 18 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 2/19/2025 by MarketBeat.com Staff
Free SGMO Stock Alerts